Updated:
Adagio Medical Holdings
Adagio Medical Holdings, structured as a special purpose acquisition company (SPAC) target, represents the commercial vehicle for Adagio Medical, a...
Adagio Medical Holdings
Adagio Medical Holdings, structured as a special purpose acquisition company (SPAC) target, represents the commercial vehicle for Adagio Medical, a developer of intelligent catheter systems for cardiac arrhythmias. The firm's core innovation centers on ultra-low temperature cryoablation, designed to create contiguous, transmural lesions for persistent atrial fibrillation and monomorphic ventricular tachycardia. Unlike conventional radiofrequency or single-point cryoablation, Adagio's platform uses a continuous lesion-creation methodology at extreme cold temperatures, targeting durable outcomes with reduced procedure times. The company's primary deployment is direct investment into its own catheter development and clinical trial infrastructure rather than third-party fund commitments. Its iCLAS system and vCLAS catheter have been studied in multiple clinical evaluations, including trials for persistent atrial fibrillation in Europe and ventricular tachycardia ablation in Canada. Adagio's regulatory strategy spans CE Mark clearance in the European Union and ongoing clinical work under FDA investigational device exemption in the United States, with the firm actively enrolling in the FULCRUM-VT pivotal trial for ventricular tachycardia as of 2024. Since combining with the former Aja Holdco SPAC structure, Adagio Medical Holdings lists under the ticker ADGM on Nasdaq. The firm's total deployment is reflected in public financial filings — cash positions, R&D spend, and commercialization expense released quarterly — rather than a traditional AUM framework. Early 2024 balance sheet disclosures showed approximately $43 million in cash and equivalents post-merger. Professional operations are led by CEO Olav Bergheim, with clinical leadership from Dr. Atul Verma, Chief Medical Officer, and engineering direction from co-founder Randy Werneth. The company maintains facilities in Laguna Hills, California and has European clinical operations out of the Netherlands. Structurally, Adagio differs from most device companies by entering public markets through a de-SPAC transaction rather than a traditional IPO or venture-backed acquisition. This creates a publicly-accountable capital base directly tied to product milestones, patent prosecution, and clinical trial data readouts — a structure that subjects its deployment strategy to quarterly earnings visibility uncommon in venture-stage medtech.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Sector focus
Frequently asked questions
What technology platform defines Adagio Medical's investment thesis?
Adagio Medical's platform centers on ultra-low temperature cryoablation, which creates continuous, linear lesions in cardiac tissue to treat complex arrhythmias. Unlike conventional cryoablation that relies on balloon-based single-shot pulmonary vein isolation, Adagio's catheters use extreme cold to produce durable, transmural lesions that more closely replicate surgical ablation lesion sets. The firm's iCLAS system is designed for persistent atrial fibrillation, while the vCLAS catheter targets ventricular tachycardia — a significantly underserved electrophysiology market.
What is Adagio Medical's regulatory status and clinical evidence profile?
Adagio holds CE Mark certification for its iCLAS system in Europe, supported by clinical data from centers in multiple EU countries and Canada. In the United States, the firm operates under FDA investigational device exemption and is enrolling patients in the FULCRUM-VT pivotal trial for ventricular tachycardia ablation as of 2024. Published clinical results include Canadian experience with ultra-low temperature cryoablation for both atrial fibrillation and ventricular tachycardia, demonstrating acute procedural success and acceptable safety profiles in early cohorts (per Journal of Cardiovascular Electrophysiology, 2023).
How does Adagio Medical Holdings relate to the operating company Adagio Medical?
Adagio Medical Holdings is the publicly-listed parent entity formed through the 2024 merger of Adagio Medical with Aja Holdco, a special purpose acquisition company. The underlying operating company, Adagio Medical, was founded to develop and commercialize the ultra-low temperature cryoablation platform. Post-merger, Adagio Medical operates as a subsidiary of the Nasdaq-listed holding company, with Olav Bergheim serving as CEO of the combined entity. This structure provides public-market access to capital while maintaining focus on device development and clinical execution.
Who leads the clinical and technical development at Adagio Medical?
Clinical leadership comes from Chief Medical Officer Dr. Atul Verma, a prominent electrophysiologist known for pioneering advanced ablation techniques at Southlake Regional Health Centre and the University of Toronto. Engineering and technical direction is led by co-founder Randy Werneth, whose background includes catheter development roles at multiple medical device companies prior to Adagio. CEO Olav Bergheim brings medtech executive experience from prior roles in cardiovascular device commercialization.
What is Adagio Medical's market positioning relative to established electrophysiology competitors?
Adagio enters a field dominated by Johnson & Johnson MedTech (Biosense Webster), Abbott, Boston Scientific, and Medtronic — all offering radiofrequency or pulsed-field ablation systems for atrial fibrillation. Adagio differentiates on the physics of its energy source: ultra-low temperature cryoablation at approximately -196°C, which creates lesion continuity through different biophysics than heat-based ablation. The firm's primary niche is persistent atrial fibrillation and ventricular tachycardia, segments where existing balloon-based cryoablation and point-by-point radiofrequency have shown limitations in durability.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: